The majority of patients (89%) were Child-Pugh score 5, and 64.1% were BCLC stage A. Compared with the tertiary prevention group, patients in the secondary prevention failure group had significantly lower HBV viral loads, ALT, AST levels, smaller tumor size, and earlier BCLC stage. The gene discussed is GPT; the disease is neoplasm.